Brief: Ampio Suspends Patient Enrollment In Its Phase 3 Study Of Ampion

Ampio Pharmaceuticals

24/03/2020 12:41

March 24 (Reuters) - Ampio Pharmaceuticals Inc  AMPE.A :
    * AMPIO SUSPENDS PATIENT ENROLLMENT IN ITS PHASE 3 STUDY OF
AMPION
FOR SEVERE OSTEOARTHRITIS OF THE KNEE AND EXPLORES OTHER OPTIONS
TO COMPLETE TRIAL
    * AMPIO PHARMACEUTICALS INC - IT IS POSSIBLE THAT COVID-19
PANDEMIC MAY PREVENT COMPLETION OF AP-013 TRIAL AT THIS TIME OR
AT ALL.
    * AMPIO PHARMACEUTICALS INC - FOCUSING ON INVESTIGATING
POTENTIAL
USE OF NEBULIZED AMPION FOR TREATMENT OF A SERIOUS COMPLICATION
OF COVID-19

Source text for Eikon:  ID:nPncbGchWa 
Further company coverage:  AMPE.A 

 ((Reuters.Briefs@thomsonreuters.com;))